Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Erratum (v51,p3592)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Forbes, J. M.
Right arrow Articles by Osicka, T. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Forbes, J. M.
Right arrow Articles by Osicka, T. M.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes 51:3274-3282, 2002
© 2002 by the American Diabetes Association, Inc.

Reduction of the Accumulation of Advanced Glycation End Products by ACE Inhibition in Experimental Diabetic Nephropathy

Josephine M. Forbes1, Mark E. Cooper1, Vicki Thallas1, Wendy C. Burns1, Merlin C. Thomas1, Gail C. Brammar1, Fiona Lee1, Sharon L. Grant1, Louise A. Burrell1, George Jerums2, and Tanya M. Osicka2

1 Department of Medicine, University of Melbourne, Austin and Repatriation Medical Centre, West Heidelberg, Australia
2 Department of Endocrinology, Austin and Repatriation Medical Centre, Heidelberg, Australia

The effect of ACE inhibition on the formation of advanced glycation end products (AGEs) and oxidative stress was explored. Streptozocin-induced diabetic animals were randomized to no treatment, the ACE inhibitor ramipril (3 mg/l), or the AGE formation inhibitor aminoguanidine (1 g/l) and followed for 12 weeks. Control groups were followed concurrently. Renal AGE accumulation, as determined by immunohistochemistry and both serum and renal fluorescence, were increased in diabetic animals. This was attenuated by both ramipril and aminoguanidine to a similar degree. Nitrotyrosine, a marker of protein oxidation, also followed a similar pattern. The receptor for AGEs, gene expression of the membrane-bound NADPH oxidase subunit gp91phox, and nuclear transcription factor-{kappa}B were all increased by diabetes but remained unaffected by either treatment regimen. Two other AGE receptors, AGE R2 and AGE R3, remained unchanged for the duration of the study. The present study has identified a relationship between the renin-angiotensin system and the accumulation of AGEs in experimental diabetic nephropathy that may be linked through oxidative stress


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
Y. Izuhara, M. Nangaku, S. Takizawa, S. Takahashi, J. Shao, H. Oishi, H. Kobayashi, C. v. Y. d. Strihou, and T. Miyata
A novel class of advanced glycation inhibitors ameliorates renal and cardiovascular damage in experimental rat models
Nephrol. Dial. Transplant., October 10, 2007; (2007) gfm601v1.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
E. N. Lavrentyev, A. M. Estes, and K. U. Malik
Mechanism of High Glucose Induced Angiotensin II Production in Rat Vascular Smooth Muscle Cells
Circ. Res., August 31, 2007; 101(5): 455 - 464.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
M. L. Onozato, A. Tojo, N. Kobayashi, A. Goto, H. Matsuoka, and T. Fujita
Dual blockade of aldosterone and angiotensin II additively suppresses TGF-{beta} and NADPH oxidase in the hypertensive kidney
Nephrol. Dial. Transplant., May 1, 2007; 22(5): 1314 - 1322.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
M. T. Coughlan, V. Thallas-Bonke, J. Pete, D. M. Long, A. Gasser, D. C. K. Tong, M. Arnstein, S. R. Thorpe, M. E. Cooper, and J. M. Forbes
Combination Therapy with the Advanced Glycation End Product Cross-Link Breaker, Alagebrium, and Angiotensin Converting Enzyme Inhibitors in Diabetes: Synergy or Redundancy?
Endocrinology, February 1, 2007; 148(2): 886 - 895.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. Rev.Home page
K. Bedard and K.-H. Krause
The NOX Family of ROS-Generating NADPH Oxidases: Physiology and Pathophysiology
Physiol Rev, January 1, 2007; 87(1): 245 - 313.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. Rev.Home page
P. Pacher, J. S. Beckman, and L. Liaudet
Nitric Oxide and Peroxynitrite in Health and Disease
Physiol Rev, January 1, 2007; 87(1): 315 - 424.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
F. Persson, P. Rossing, P. Hovind, C. D.A. Stehouwer, C. Schalkwijk, L. Tarnow, and H.-H. Parving
Irbesartan Treatment Reduces Biomarkers of Inflammatory Activity in Patients With Type 2 Diabetes and Microalbuminuria: An IRMA 2 Substudy
Diabetes, December 1, 2006; 55(12): 3550 - 3555.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
S. Giunti, D. Barit, and M. E. Cooper
Mechanisms of Diabetic Nephropathy: Role of Hypertension
Hypertension, October 1, 2006; 48(4): 519 - 526.
[Full Text] [PDF]

Home page
 CirculationHome page
A. Goldin, J. A. Beckman, A. M. Schmidt, and M. A. Creager
Advanced Glycation End Products: Sparking the Development of Diabetic Vascular Injury
Circulation, August 8, 2006; 114(6): 597 - 605.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
A. G. Huebschmann, J. G. Regensteiner, H. Vlassara, and J. E.B. Reusch
Diabetes and Advanced Glycoxidation End Products.
Diabetes Care, June 1, 2006; 29(6): 1420 - 1432.
[Full Text] [PDF]

Home page
 DiabetesHome page
J. M. Starkey, S. J. Haidacher, W. S. LeJeune, X. Zhang, B. C. Tieu, S. Choudhary, A. R. Brasier, L. A. Denner, and R. G. Tilton
Diabetes-Induced Activation of Canonical and Noncanonical Nuclear Factor-{kappa}B Pathways in Renal Cortex.
Diabetes, May 1, 2006; 55(5): 1252 - 1259.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
T. Miyata and C. van Ypersele de Strihou
Renoprotection of angiotensin receptor blockers: beyond blood pressure lowering
Nephrol. Dial. Transplant., April 1, 2006; 21(4): 846 - 849.
[Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
D. Feliers, Y. Gorin, G. Ghosh-Choudhury, H. E. Abboud, and B. S. Kasinath
Angiotensin II stimulation of VEGF mRNA translation requires production of reactive oxygen species
Am J Physiol Renal Physiol, April 1, 2006; 290(4): F927 - F936.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes Spectr.Home page
P. M. Hall
Prevention of Progression in Diabetic Nephropathy
Diabetes Spectr, January 1, 2006; 19(1): 18 - 24.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
Y. Kikuchi, T. Imakiire, T. Hyodo, T. Kushiyama, K. Higashi, N. Hyodo, S. Suzuki, and S. Miura
Advanced glycation end-product induces fractalkine gene upregulation in normal rat glomeruli
Nephrol. Dial. Transplant., December 1, 2005; 20(12): 2690 - 2696.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
Y. Izuhara, M. Nangaku, R. Inagi, N. Tominaga, T. Aizawa, K. Kurokawa, C. van Ypersele de Strihou, and T. Miyata
Renoprotective Properties of Angiotensin Receptor Blockers beyond Blood Pressure Lowering
J. Am. Soc. Nephrol., December 1, 2005; 16(12): 3631 - 3641.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
R. Meerwaldt, J. W.L. Hartog, R. Graaff, R. J. Huisman, T. P. Links, N. C. den Hollander, S. R. Thorpe, J. W. Baynes, G. Navis, R. O.B. Gans, et al.
Skin Autofluorescence, a Measure of Cumulative Metabolic Stress and Advanced Glycation End Products, Predicts Mortality in Hemodialysis Patients
J. Am. Soc. Nephrol., December 1, 2005; 16(12): 3687 - 3693.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y. Gorin, K. Block, J. Hernandez, B. Bhandari, B. Wagner, J. L. Barnes, and H. E. Abboud
Nox4 NAD(P)H Oxidase Mediates Hypertrophy and Fibronectin Expression in the Diabetic Kidney
J. Biol. Chem., November 25, 2005; 280(47): 39616 - 39626.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
S. Genuth, W. Sun, P. Cleary, D. R. Sell, W. Dahms, J. Malone, W. Sivitz, V. M. Monnier, and for the DCCT Skin Collagen Ancillary Study Group
Glycation and Carboxymethyllysine Levels in Skin Collagen Predict the Risk of Future 10-Year Progression of Diabetic Retinopathy and Nephropathy in the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications Participants With Type 1 Diabetes
Diabetes, November 1, 2005; 54(11): 3103 - 3111.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
M. C. Thomas, C. Tikellis, W. M. Burns, K. Bialkowski, Z. Cao, M. T. Coughlan, K. Jandeleit-Dahm, M. E. Cooper, and J. M. Forbes
Interactions between Renin Angiotensin System and Advanced Glycation in the Kidney
J. Am. Soc. Nephrol., October 1, 2005; 16(10): 2976 - 2984.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
J. B. de Haan, N. Stefanovic, D. Nikolic-Paterson, L. L. Scurr, K. D. Croft, T. A. Mori, P. Hertzog, I. Kola, R. C. Atkins, and G. H. Tesch
Kidney expression of glutathione peroxidase-1 is not protective against streptozotocin-induced diabetic nephropathy
Am J Physiol Renal Physiol, September 1, 2005; 289(3): F544 - F551.
[Abstract] [Full Text] [PDF]

Home page
 J Mol EndocrinolHome page
S. Kooptiwut, M. Kebede, S. Zraika, S. Visinoni, K. Aston-Mourney, J. Favaloro, C. Tikellis, M. C Thomas, J. M Forbes, M. E Cooper, et al.
High glucose-induced impairment in insulin secretion is associated with reduction in islet glucokinase in a mouse model of susceptibility to islet dysfunction
J. Mol. Endocrinol., August 1, 2005; 35(1): 39 - 48.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
J. M. Forbes, S. R. Thorpe, V. Thallas-Bonke, J. Pete, M. C. Thomas, E. R. Deemer, S. Bassal, A. El-Osta, D. M. Long, S. Panagiotopoulos, et al.
Modulation of Soluble Receptor for Advanced Glycation End Products by Angiotensin-Converting Enzyme-1 Inhibition in Diabetic Nephropathy
J. Am. Soc. Nephrol., August 1, 2005; 16(8): 2363 - 2372.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
R. Harris
Angiotensin-Converting Enzyme Inhibition in Diabetic Nephropathy: It's All the RAGE
J. Am. Soc. Nephrol., August 1, 2005; 16(8): 2251 - 2253.
[Full Text] [PDF]

Home page
 Ann. N. Y. Acad. Sci.Home page
A S JANUSZEWSKI, M C THOMAS, S J CHUNG, C S KARSCHIMKUS, K G ROWLEY, C NELSON, D O'NEAL, Z WANG, J D BEST, and A J JENKINS
Plasma Low-Molecular Weight Fluorescence in Type 1 Diabetes Mellitus
Ann. N.Y. Acad. Sci., June 1, 2005; 1043(1): 655 - 661.
[Abstract] [Full Text] [PDF]

Home page
 Ann. N. Y. Acad. Sci.Home page
M. T. COUGHLAN, M. E. COOPER, and J. M. FORBES
Can Advanced Glycation End Product Inhibitors Modulate More than One Pathway to Enhance Renoprotection in Diabetes?
Ann. N.Y. Acad. Sci., June 1, 2005; 1043(1): 750 - 758.
[Abstract] [Full Text] [PDF]

Home page
 Ann. N. Y. Acad. Sci.Home page
J. L. FIGAROLA, S. SCOTT, S. LOERA, B. XI, T. SYNOLD, and S. RAHBAR
Renoprotective and Lipid-Lowering Effects of LR Compounds, Novel Advanced Glycation End Product Inhibitors, in Streptozotocin-Induced Diabetic Rats
Ann. N.Y. Acad. Sci., June 1, 2005; 1043(1): 767 - 776.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
B. F. Schrijvers, A. S. De Vriese, and A. Flyvbjerg
From Hyperglycemia to Diabetic Kidney Disease: The Role of Metabolic, Hemodynamic, Intracellular Factors and Growth Factors/Cytokines
Endocr. Rev., December 1, 2004; 25(6): 971 - 1010.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
Q. Fan, J. Liao, M. Kobayashi, M. Yamashita, L. Gu, T. Gohda, Y. Suzuki, L. N. Wang, S. Horikoshi, and Y. Tomino
Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice
Nephrol. Dial. Transplant., December 1, 2004; 19(12): 3012 - 3020.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. C. Thomas, C. Tikellis, P. Kantharidis, W. C. Burns, M. E. Cooper, and J. M. Forbes
The Role of Advanced Glycation in Reduced Organic Cation Transport Associated with Experimental Diabetes
J. Pharmacol. Exp. Ther., November 1, 2004; 311(2): 456 - 466.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
A. Prasad and A. A. Quyyumi
Renin-Angiotensin System and Angiotensin Receptor Blockers in the Metabolic Syndrome
Circulation, September 14, 2004; 110(11): 1507 - 1512.
[Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
M. Lassila, K. K. Seah, T. J. Allen, V. Thallas, M. C. Thomas, R. Candido, W. C. Burns, J. M. Forbes, A. C. Calkin, M. E. Cooper, et al.
Accelerated Nephropathy in Diabetic Apolipoprotein E-Knockout Mouse: Role of Advanced Glycation End Products
J. Am. Soc. Nephrol., August 1, 2004; 15(8): 2125 - 2138.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
F. T.H. Lee, Z. Cao, D. M. Long, S. Panagiotopoulos, G. Jerums, M. E. Cooper, and J. M. Forbes
Interactions between Angiotensin II and NF-{kappa}B-Dependent Pathways in Modulating Macrophage Infiltration in Experimental Diabetic Nephropathy
J. Am. Soc. Nephrol., August 1, 2004; 15(8): 2139 - 2151.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
J. M. Forbes, L. T. L. Yee, V. Thallas, M. Lassila, R. Candido, K. A. Jandeleit-Dahm, M. C. Thomas, W. C. Burns, E. K. Deemer, S. R. Thorpe, et al.
Advanced Glycation End Product Interventions Reduce Diabetes-Accelerated Atherosclerosis
Diabetes, July 1, 2004; 53(7): 1813 - 1823.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
F. R. DeRubertis, P. A. Craven, M. F. Melhem, and E. M. Salah
Attenuation of Renal Injury in db/db Mice Overexpressing Superoxide Dismutase: Evidence for Reduced Superoxide-Nitric Oxide Interaction
Diabetes, March 1, 2004; 53(3): 762 - 768.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
A. Flyvbjerg, L. Denner, B. F. Schrijvers, R. G. Tilton, T. H. Mogensen, S. R. Paludan, and R. Rasch
Long-Term Renal Effects of a Neutralizing RAGE Antibody in Obese Type 2 Diabetic Mice
Diabetes, January 1, 2004; 53(1): 166 - 172.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
J. M. Forbes, M. E. Cooper, M. D. Oldfield, and M. C. Thomas
Role of Advanced Glycation End Products in Diabetic Nephropathy
J. Am. Soc. Nephrol., August 1, 2003; 14(90003): S254 - 258.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
M. Nangaku, T. Miyata, T. Sada, M. Mizuno, R. Inagi, Y. Ueda, N. Ishikawa, H. Yuzawa, H. Koike, C. van Ypersele de Strihou, et al.
Anti-Hypertensive Agents Inhibit In Vivo the Formation of Advanced Glycation End Products and Improve Renal Damage in a Type 2 Diabetic Nephropathy Rat Model
J. Am. Soc. Nephrol., May 1, 2003; 14(5): 1212 - 1222.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2002 by the American Diabetes Association.